Samuel Jackson PhD

Dr. Jackson was awarded a Ph.D. in Neurobiology in 2004 for work studying the role of the cannabinoid system in neurodegeneration related to multiple sclerosis. During postdoctoral positions at the University of Wisconsin – Madison, UCL, and QMUL, he developed and employed animal and in vitro models of demyelinating disease to probe therapeutic approaches to remyelination and neuroprotection. Following 3 years at Eli Lilly working on the neurobiology and treatment of Alzheimer’s disease, Dr. Jackson left the lab to apply his knowledge of animal and alternative modeling at the NC3Rs. He is currently managing a program of work to enable the development and uptake of human tissue-based models, microphysiological systems and other alternative methods to diverse research areas, including cancer and safety pharmacology.